Shattuck Labs (NASDAQ:STTK) Coverage Initiated by Analysts at Leerink Partners

Leerink Partners began coverage on shares of Shattuck Labs (NASDAQ:STTK) in a research note released on Monday, Marketbeat reports. The firm issued an outperform rating and a $4.00 price objective on the stock.

Shattuck Labs Stock Down 1.7 %

Shattuck Labs stock opened at $1.17 on Monday. The business’s 50-day simple moving average is $1.25 and its 200 day simple moving average is $1.61. The stock has a market cap of $55.86 million, a price-to-earnings ratio of -0.76 and a beta of 1.66. Shattuck Labs has a 12-month low of $0.94 and a 12-month high of $11.76.

Hedge Funds Weigh In On Shattuck Labs

Hedge funds have recently added to or reduced their stakes in the company. GSA Capital Partners LLP bought a new position in Shattuck Labs during the third quarter worth about $121,000. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Shattuck Labs by 44.1% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 178,228 shares of the company’s stock worth $622,000 after buying an additional 54,505 shares during the last quarter. FMR LLC boosted its holdings in Shattuck Labs by 0.4% during the third quarter. FMR LLC now owns 7,159,090 shares of the company’s stock worth $24,985,000 after buying an additional 26,460 shares during the last quarter. MetLife Investment Management LLC boosted its holdings in Shattuck Labs by 129.1% during the third quarter. MetLife Investment Management LLC now owns 24,596 shares of the company’s stock worth $86,000 after buying an additional 13,859 shares during the last quarter. Finally, Atom Investors LP bought a new position in Shattuck Labs during the third quarter worth about $35,000. Institutional investors own 58.74% of the company’s stock.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.